These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Guanidino compounds in uraemic dialysed patients. De Deyn P, Marescau B, Lornoy W, Becaus I, Lowenthal A. Clin Chim Acta; 1986 Jun 15; 157(2):143-50. PubMed ID: 3719996 [Abstract] [Full Text] [Related]
5. Guanidino compound levels in brain regions of non-dialyzed uremic patients. De Deyn PP, Marescau B, D'Hooge R, Possemiers I, Nagler J, Mahler C. Neurochem Int; 1995 Sep 15; 27(3):227-37. PubMed ID: 8520461 [Abstract] [Full Text] [Related]
6. Plasma, urinary, and erythrocyte concentrations of guanidino compounds in patients with chronic renal failure. Tanaka A, Takahashi Y, Mizokuchi M, Shimada N, Koide H. Ren Fail; 1999 Sep 15; 21(5):499-514. PubMed ID: 10516995 [Abstract] [Full Text] [Related]
7. Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice. D'Hooge R, Pei YQ, Marescau B, De Deyn PP. J Neurol Sci; 1992 Oct 15; 112(1-2):96-105. PubMed ID: 1469446 [Abstract] [Full Text] [Related]
8. Automatic system for the assay of guanidino compounds to assess uremic status and effect of hemodialysis. Nohara Y, Hanai T, Suzuki J, Matsumoto G, Iinuma F, Kubo H, Kinoshita T. Chem Pharm Bull (Tokyo); 1998 Nov 15; 46(11):1844-5. PubMed ID: 9845964 [Abstract] [Full Text] [Related]
9. Guanidino compounds in serum and cerebrospinal fluid of non-dialyzed patients with renal insufficiency. De Deyn PP, Marescau B, Cuykens JJ, Van Gorp L, Lowenthal A, De Potter WP. Clin Chim Acta; 1987 Jul 30; 167(1):81-8. PubMed ID: 3665089 [Abstract] [Full Text] [Related]
11. Liquid-chromatographic determination of guanidino compounds in plasma and erythrocyte of normal persons and uremic patients. Kikuchi T, Orita Y, Ando A, Mikami H, Fujii M, Okada A, Abe H. Clin Chem; 1981 Nov 30; 27(11):1899-902. PubMed ID: 7296840 [Abstract] [Full Text] [Related]
13. Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients. Pietrzak I, Baczyk K. Kidney Int Suppl; 2001 Feb 30; 78():S97-101. PubMed ID: 11168992 [Abstract] [Full Text] [Related]
14. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins. Dasgupta A, Malik S. Am J Nephrol; 1994 Feb 30; 14(3):162-8. PubMed ID: 7977474 [Abstract] [Full Text] [Related]
15. Gas chromatographic determination of guanidino compounds in uremic patients using glyoxal as derivatizing reagent. Majidano SA, Khuhawar MY. J Chromatogr Sci; 2012 May 30; 50(5):380-6. PubMed ID: 22392369 [Abstract] [Full Text] [Related]
16. High-performance liquid chromatographic analysis of guanidino compounds using ninhydrin reagent. II. Guanidino compounds in blood of patients on haemodialysis therapy. Hiraga Y, Kinoshita T. J Chromatogr; 1985 Aug 09; 342(2):269-75. PubMed ID: 4055949 [Abstract] [Full Text] [Related]
17. Depressed natural killer cell activity in uremia. Evidence for immunosuppressive factor in uremic sera. Asaka M, Iida H, Izumino K, Sasayama S. Nephron; 1988 Aug 09; 49(4):291-5. PubMed ID: 3261845 [Abstract] [Full Text] [Related]